{"id":61538,"date":"2025-07-07T19:07:07","date_gmt":"2025-07-07T17:07:07","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/segal-trials-contributes-to-breakthrough-flu-prevention-study-led-by-cidara-therapeutics\/"},"modified":"2025-07-07T19:07:07","modified_gmt":"2025-07-07T17:07:07","slug":"segal-trials-contributes-to-breakthrough-flu-prevention-study-led-by-cidara-therapeutics","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/segal-trials-contributes-to-breakthrough-flu-prevention-study-led-by-cidara-therapeutics\/","title":{"rendered":"Segal Trials Contributes to Breakthrough Flu Prevention Study Led by Cidara Therapeutics"},"content":{"rendered":"
\n

MIAMI LAKES, Fla.–(BUSINESS WIRE)–#AntiviralTreatment<\/a>–Segal Trials proudly announces its participation in the successful Phase 2b NAVIGATE clinical trial conducted by Cidara Therapeutics, evaluating CD388<\/b>\u2014a novel, non-vaccine, long-acting antiviral\u2014for the prevention of seasonal influenza. Dr. Steven Chavoustie<\/b> served as the Principal Investigator for the study at Segal Trials.<\/p>\n

<\/a>
<\/a><\/p>\n

\nThe NAVIGATE trial enrolled over 5,000 healthy, unvaccinated adults and met both its primary and secondary efficacy endpoints<\/b>, showing that single doses of CD388 conferred 76%, 61%, and 58% protection<\/b>, respectively, across three dosage levels. Participants were monitored for symptomatic, laboratory-confirmed influenza over a 24-week period. CD388 was well-tolerated at all doses with no unexpected safety signals<\/b> reported.<\/p>\n

\n\u201cWe are honored to have been part of a study that marks a potential paradigm shift in how we approach flu prevention,\u201d said Dr. Steven Chavoustie<\/b>, Principal Investigator at Segal Trials. \u201cA once-per-season antiviral could significantly improve access to flu protection, especially among individuals for whom vaccines may not be effective.\u201d<\/p>\n

\nUnlike vaccines, CD388 does not rely on the body\u2019s immune response, making it a promising option for those with compromised immunity or heightened risk for severe flu. This innovative approach represents a potential new standard of care for broad seasonal influenza protection.<\/p>\n

\nFollowing the trial\u2019s success, Cidara Therapeutics has submitted an End of Phase 2 meeting request to the U.S. Food and Drug Administration (FDA) to discuss the upcoming Phase 3 trial design.<\/p>\n

\nAbout Segal Trials<\/b><\/p>\n

\nFounded in 1998, Segal Trials is a privately held clinical research network with multiple sites across South Florida. Specializing in psychiatry, neurology, women\u2019s health, and general medicine, Segal Trials is committed to advancing medical research through high-quality Phase I\u2013IV trials while helping sponsors meet enrollment goals.<\/p>\n

Contacts<\/b> <\/p>\n

\nMedia Contact<\/b>
Segal Trials
\n
Email: marketing@segaltrials.com<\/a>
Website: www.segaltrials.com<\/a><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

MIAMI LAKES, Fla.–(BUSINESS WIRE)–#AntiviralTreatment–Segal Trials proudly announces its participation in the successful Phase 2b NAVIGATE clinical trial conducted by Cidara Therapeutics, evaluating CD388\u2014a novel, non-vaccine, long-acting antiviral\u2014for the prevention of seasonal influenza. Dr. Steven Chavoustie served as the Principal Investigator for the study at Segal Trials. The NAVIGATE trial enrolled over 5,000 healthy, unvaccinated adults … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-61538","6":"format-standard","7":"category-industry"},"yoast_head":"\nSegal Trials Contributes to Breakthrough Flu Prevention Study Led by Cidara Therapeutics - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/segal-trials-contributes-to-breakthrough-flu-prevention-study-led-by-cidara-therapeutics\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Segal Trials Contributes to Breakthrough Flu Prevention Study Led by Cidara Therapeutics - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"MIAMI LAKES, Fla.–(BUSINESS WIRE)–#AntiviralTreatment–Segal Trials proudly announces its participation in the successful Phase 2b NAVIGATE clinical trial conducted by Cidara Therapeutics, evaluating CD388\u2014a novel, non-vaccine, long-acting antiviral\u2014for the prevention of seasonal influenza. Dr. Steven Chavoustie served as the Principal Investigator for the study at Segal Trials. The NAVIGATE trial enrolled over 5,000 healthy, unvaccinated adults ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/segal-trials-contributes-to-breakthrough-flu-prevention-study-led-by-cidara-therapeutics\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2025-07-07T17:07:07+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20250707705610\/en\/2516402\/22\/ST_stck_white_bg.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/segal-trials-contributes-to-breakthrough-flu-prevention-study-led-by-cidara-therapeutics\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/segal-trials-contributes-to-breakthrough-flu-prevention-study-led-by-cidara-therapeutics\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Segal Trials Contributes to Breakthrough Flu Prevention Study Led by Cidara Therapeutics\",\"datePublished\":\"2025-07-07T17:07:07+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/segal-trials-contributes-to-breakthrough-flu-prevention-study-led-by-cidara-therapeutics\\\/\"},\"wordCount\":306,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/segal-trials-contributes-to-breakthrough-flu-prevention-study-led-by-cidara-therapeutics\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20250707705610\\\/en\\\/2516402\\\/22\\\/ST_stck_white_bg.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/segal-trials-contributes-to-breakthrough-flu-prevention-study-led-by-cidara-therapeutics\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/segal-trials-contributes-to-breakthrough-flu-prevention-study-led-by-cidara-therapeutics\\\/\",\"name\":\"Segal Trials Contributes to Breakthrough Flu Prevention Study Led by Cidara Therapeutics - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/segal-trials-contributes-to-breakthrough-flu-prevention-study-led-by-cidara-therapeutics\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/segal-trials-contributes-to-breakthrough-flu-prevention-study-led-by-cidara-therapeutics\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20250707705610\\\/en\\\/2516402\\\/22\\\/ST_stck_white_bg.jpg\",\"datePublished\":\"2025-07-07T17:07:07+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/segal-trials-contributes-to-breakthrough-flu-prevention-study-led-by-cidara-therapeutics\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/segal-trials-contributes-to-breakthrough-flu-prevention-study-led-by-cidara-therapeutics\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/segal-trials-contributes-to-breakthrough-flu-prevention-study-led-by-cidara-therapeutics\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20250707705610\\\/en\\\/2516402\\\/22\\\/ST_stck_white_bg.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20250707705610\\\/en\\\/2516402\\\/22\\\/ST_stck_white_bg.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/segal-trials-contributes-to-breakthrough-flu-prevention-study-led-by-cidara-therapeutics\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Segal Trials Contributes to Breakthrough Flu Prevention Study Led by Cidara Therapeutics\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Segal Trials Contributes to Breakthrough Flu Prevention Study Led by Cidara Therapeutics - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/segal-trials-contributes-to-breakthrough-flu-prevention-study-led-by-cidara-therapeutics\/","og_locale":"en_US","og_type":"article","og_title":"Segal Trials Contributes to Breakthrough Flu Prevention Study Led by Cidara Therapeutics - Pharma Trend","og_description":"MIAMI LAKES, Fla.–(BUSINESS WIRE)–#AntiviralTreatment–Segal Trials proudly announces its participation in the successful Phase 2b NAVIGATE clinical trial conducted by Cidara Therapeutics, evaluating CD388\u2014a novel, non-vaccine, long-acting antiviral\u2014for the prevention of seasonal influenza. Dr. Steven Chavoustie served as the Principal Investigator for the study at Segal Trials. The NAVIGATE trial enrolled over 5,000 healthy, unvaccinated adults ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/segal-trials-contributes-to-breakthrough-flu-prevention-study-led-by-cidara-therapeutics\/","og_site_name":"Pharma Trend","article_published_time":"2025-07-07T17:07:07+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20250707705610\/en\/2516402\/22\/ST_stck_white_bg.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/segal-trials-contributes-to-breakthrough-flu-prevention-study-led-by-cidara-therapeutics\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/segal-trials-contributes-to-breakthrough-flu-prevention-study-led-by-cidara-therapeutics\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Segal Trials Contributes to Breakthrough Flu Prevention Study Led by Cidara Therapeutics","datePublished":"2025-07-07T17:07:07+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/segal-trials-contributes-to-breakthrough-flu-prevention-study-led-by-cidara-therapeutics\/"},"wordCount":306,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/segal-trials-contributes-to-breakthrough-flu-prevention-study-led-by-cidara-therapeutics\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20250707705610\/en\/2516402\/22\/ST_stck_white_bg.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/segal-trials-contributes-to-breakthrough-flu-prevention-study-led-by-cidara-therapeutics\/","url":"https:\/\/pharma-trend.com\/en\/segal-trials-contributes-to-breakthrough-flu-prevention-study-led-by-cidara-therapeutics\/","name":"Segal Trials Contributes to Breakthrough Flu Prevention Study Led by Cidara Therapeutics - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/segal-trials-contributes-to-breakthrough-flu-prevention-study-led-by-cidara-therapeutics\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/segal-trials-contributes-to-breakthrough-flu-prevention-study-led-by-cidara-therapeutics\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20250707705610\/en\/2516402\/22\/ST_stck_white_bg.jpg","datePublished":"2025-07-07T17:07:07+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/segal-trials-contributes-to-breakthrough-flu-prevention-study-led-by-cidara-therapeutics\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/segal-trials-contributes-to-breakthrough-flu-prevention-study-led-by-cidara-therapeutics\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/segal-trials-contributes-to-breakthrough-flu-prevention-study-led-by-cidara-therapeutics\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20250707705610\/en\/2516402\/22\/ST_stck_white_bg.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20250707705610\/en\/2516402\/22\/ST_stck_white_bg.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/segal-trials-contributes-to-breakthrough-flu-prevention-study-led-by-cidara-therapeutics\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Segal Trials Contributes to Breakthrough Flu Prevention Study Led by Cidara Therapeutics"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/61538","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=61538"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/61538\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=61538"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=61538"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=61538"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}